THURSDAY, Jan. 18, 2024 -- Testosterone treatment does not result in a lower incidence of clinical fractures among middle-aged and older men with hypogonadism, according to a study published in the Jan. 18 issue of the New England Journal of Medicine. The researchers found that a clinical fracture occurred in 3.50 and 2.46 percent of participants in the testosterone and placebo groups, respectively, after a median follow-up of 3.19 years (hazard ratio, 1.43). For all other fracture end points, the fracture incidence also seemed higher in the testosterone group. "We did not expect these results, because most previous studies showed that testosterone improved many measures of bone structure and quality," the authors write. Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
News for Health Professionals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.